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Human pancreatic carcinoma is an extremely aggressive disease
that currently is the fourth leading cause of cancer death in males
and females in the USA (Landis et al, 1999). Several studies have
shown that genes such as p53,  Ki-ras,  p16 and  DPC4 are
frequently mutated in this cancer (Apple et al, 1996; Hahn et al,
1996; Lynch et al, 1996). These genetic aberrations are similar to
those detected in other human cancers and are unlikely to be the
reason why pancreatic cancer is more aggressive than others. It is
possible that activation of mitogenic pathways by autocrine
growth factors contributes to the devastating nature of pancreatic
cancer (Korc, 1991). 
Autocrine growth can occur when a cell co-expresses a
membrane-bound growth factor receptor and soluble ligand(s) for
this receptor. Over the past decade, a variety of autocrine growth
pathways have been implicated in the pathogenesis of human
cancers. Techniques such as radioligand binding analysis, column
chromatography and immunohistochemistry have demonstrated
the presence of receptors and ligands in tumour tissues and in cell
lines. In pancreatic cancer cells, these receptors and ligands are
thought to collectively provide the cell with a trophic signal (Korc,
1991; Wang et al, 1996). Previous studies have demonstrated that
exposure of these cells to recombinant growth factors such as
transforming growth factor a (TGFa) (Korc, 1991), amphiregulin
(Munehiro et al, 1994) or insulin-like growth factor-1 (IGF-I)
(Ohmura et al, 1990) produces modest effects on cell proliferation.
It is possible that stimulation of growth pathways by endogenous
growth factors, produced by cells in culture, could explain the
poor response to exogenous factors. In the current study, we have
investigated the relative importance of different autocrine growth
pathways in pancreatic cancer. The results presented below indi-
cate that growth factor receptors and ligands expressed by pancre-
atic cancer cells do not necessarily constitute a functional
autocrine growth pathway in vitro. 
MATERIALS AND METHODS 
Materials 
Porcine heparin was obtained from Sigma Chemical Company
(St. Louis, MO). Recombinant human EGF, TGFa and amphireg-
ulin (long form) were from Intergen (Purchase, NY). The EGF
receptor tyrosine kinase inhibitor AG1478 and the MEK inhibitor
PD098059 were obtained from Calbiochem (La Jolla, CA) and
dissolved in dimethyl sulphoxide. The final concentration of
solvent in the well was not more than 0.1% (shown to have no
effect on proliferation). The TGFa-neutralizing polyclonal anti-
serum was purchased from R&D Systems (Minneapolis, MN).
The amphiregulin-neutralizing monoclonal antibody, 16.21.28,
was provided by Dr Bruce Cohen, Bristol Myers Squibb (Seattle,
WA) and the IGF-I receptor monoclonal antibody, aIR3 (Kull et
al, 1983), was provided by Dr. Steve Jacobs (Burroughs Wellcome
Co., Research Triangle Park, NC). The GRP receptor antagonist
RC-3950-II and the synthetic human EGF B-loop analogue,
[Abu20,31]hEGF(20–31)-NH2, were synthesized and purified as
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reagents used to immunoprecipitate and assay ERK1 and ERK2
activity were supplied by New England Biolabs Incorporated
(Beverly, MA) and used as described in the kit instruction manual
(version 1.3). The Prism Ready Reaction DyeDeoxy Terminator
Cycle Sequencing Kit was purchased from Perkin Elmer (Foster
City, CA). Ampliscribe T7 RNA polymerase solution, nucleotide
triphosphates and dithiothreitol were obtained from Epicenter
Technologies (Madison, WI). RT-PCR reagents were purchased
from Perkin Elmer (Foster City, CA). 
Receptor binding 
Analysis was performed as described previously (Wang et al,
1996). Cells were harvested, resuspended in binding buffer and
seeded in 96-well filter plates (100 000 cells per well). [125I]-
labelled EGF, GRP, IGF-I or insulin (20 000 cpm) was added to
each well along with various concentrations of unlabelled EGF,
bombesin or insulin. Filter plates were incubated at 37˚C in an
atmosphere of 5% CO2 for 120 minutes. Binding was terminated
by rapid filtration using a 96-well plate vacuum manifold. The
individual wells were subsequently washed twice with 250 ml of
ice-cold wash buffer and the cell-surface-associated radioactivity
was counted. 
Gel chromatography of TGFa, bombesin and IGF-I-like
immunoreactivity in conditioned medium 
The peptide fraction of HPAF conditioned medium (1 L) was
adsorbed on a SepPak cartridge and eluted with a solution (2 ml)
of 30% acetonitrile in water containing 0.1% trifluoroacetic acid.
This solution (100 ml) was applied to a Superdex Peptide HR10/30
size exclusion column (0.5 ml min–1, 0.6 Mpa) which had been
equilibrated with the same solvent. Recombinant human TGFa,
synthetic mammalian bombesin analogues and recombinant IGF-I
were similarly chromatographed. Peptide-like immunoreactivity in
column fractions was measured using specific radioimmunoas-
says. The TGFa and IGF-I assays show no significant cross-
reactivity with other growth factors (Skullman et al, 1994). The
bombesin assay measures gastrin-releasing peptide (GRP) and
neuromedin C (NMC) equally (Wang et al, 1996). 
Cell culture 
HPAF, CAPAN-2, SW1990 and PANC-1 cells were obtained from
the American Type Culture Collection (Rockville, MD). The
HPAF cells used in this study had been adapted to serum-free
culture and were routinely maintained in IMDM. McCoy’s 5A
Medium (CAPAN-2), L-15 Medium Leibovitz (SW1990), or
DMEM (PANC-1) media were supplemented with 10% fetal
bovine serum. All cell culture media contained 1% antibiotic-
antimycotic solution and all the cell lines were cultured at 37˚C in
a humidified sterile atmosphere of 5% CO2 except SW1990, which
was grown in a CO2-free environment. Each series of experiments
was performed on cells within 5 passages. 
Growth studies 
HPAF, PANC-1, SW1990 (35 000 well–1) or CAPAN-2 cells 
(50 000 well–1) were seeded in 24-well plates and grown for 72
hours in the above culture conditions. Media were then removed
and the cells were washed with phosphate buffer (500 ml). The
appropriate serum-free medium (2 ml) was then added to each
well. In control experiments, cells continued to receive fresh
serum-free medium every 12 hours (Figure 1). Otherwise, cells
remained in the same medium for the duration of the experiment
(continuous culture). Inhibitors used to implicate specific recep-
tors or ligands in the autocrine process were added to medium at
the beginning of the continuous culture. For cell cycle analysis,
ERK1 and ERK2 assays and c-fos and c-jun mRNA quantification,
CAPAN-2 cells (1.5 million) were cultured in T-25 culture flasks
for different times and processed as described below. 
[3H-methyl] thymidine incorporation 
At the end of incubations, medium was removed and cells were
washed with phosphate buffer. Cells were incubated with 500 ml of
[3H-methyl] thymidine solution (0.5 mCi well–1) for 2 hours at
37˚C. After the labelling period, the cells were precipitated with
glacial acetic acid:methanol (1:3, v/v) and then washed with a
solution of 80% (v/v) methanol in water. DNA in the acid-
insoluble fraction was dissolved by addition of 0.5 M NaOH (300
ml) and radioactivity contained in aliquots (100 ml) was counted in
a liquid scintillation counter (LKB Wallac, Turku, Finland). 
Cell number 
The number of cells in each well was determined by harvesting the
cells with trypsin-EDTA solution (500 ml well–1) and counting
cells in an aliquot (100 ml) on a Z1 Coulter Counter (Coulter
Scientific Instruments, Hialeah, FL). 
Cell cycle analysis 
Cells were cultured as described above and harvested with trypsin-
EDTA solution (2 ml) which was then diluted with phosphate
buffer (5 ml). Samples were centrifuged at 1000 g for 10 minutes
and pellets resuspended in phosphate buffer (500 ml). Ice-cold
ethanol (1 ml) was added to each cell suspension, which was then
incubated for 12 hours at 4˚C. Tube contents were centrifuged at
500 g for 10 minutes and the resultant pellets were washed with
phosphate buffer (1 ml). Following centrifugation at 500 g for 10
minutes, pellets were reconstituted in the Telford reagent (1 ml)
and shaken for 12 hours in the dark at 4˚C. Fluorescence emission
between 580 nm and 750 nm was determined using a FACScan. 
Immunoprecipitation and Western blot analysis 
Cells were washed with ice-cold phosphate buffer (5 ml), incu-
bated with lysis buffer (500 ml) on ice for 1 min and snap-frozen
on liquid nitrogen. The thawed samples were collected using a cell
scraper and sonicated 3 times on ice. Lysates were clarified by
centrifugation at 12 000 g for 10 minutes at 4˚C and protein
concentration in the samples was determined using the BioRad DC
protein kit. ERK1 and ERK2 were immunoprecipitated from
lysates and assayed for activity according to the manufacturer. 
Quantitative RT-PCR 
The phosphormidite method of olignonucleotide synthesis was
used to synthesize primers for RT-PCR of c-fos (forward: 
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TGGCTGCAGCCATC-3) or c-jun (forward: 5¢-CTGTCCCCCAT-
CGACATGGAGT-3¢;reverse:5¢-AAGGAGTACTACAGAAGC-
ATCTAC-3¢) mRNA. Competitor RNA molecules for c-fos or
c-jun were produced by PCR-amplifying sequences from the
pGL2 basic plasmid (c-fos; 1470–1588, c-jun; 1063–1619) and
cloning them into pCR2.1. The recognition sequences for the
primers listed above were also engineered into these sequences.
Clones were sequenced to verify correct insert orientation and then
transcribed in vitro using T7 RNA polymerase (0.1 mg DNA per
incubation). The transcription template (pCR2.1) was eliminated
with DNase I (verified by PCR analysis) and RNA remaining was
precipitated using 2.5 M ammonium acetate. Competitor RNA
was first quantified by measuring the absorbance at 260 nm and
then stored at –80˚C. Quantitative analysis of c-fos or c-jun
mRNAs was performed by incubating a sample of total cellular
RNA (0.5 mg) with various amounts of competitor RNA as indi-
cated in the legend to Figure 7. The mRNA and competitor RNA
were co-reverse transcribed and amplified using either the c-fos or
c-jun primer pairs. 
Data analysis 
Statistical analysis of data was performed using a paired analysis
of variance with Dunnett’s multiple comparisons test as a post-test
for individual comparisons to appropriate control data. Digital
analysis of GST-Elk-1 phosphorylation and quantitative RT-PCR
reaction products was performed using the UV Gel Documenta-
tion System. For the later, the log10 of the cRNA/mRNA band
intensity was plotted against the log10 of the cRNA concentration
of each reaction tube. Linear regression analysis of the data points
was performed using the Prism II software package. The inverse
log10 of the x-intercept corresponded to the amount of mRNA in
the total RNA analysed and mRNA levels were expressed as
moles per mg of total RNA. 
RESULTS 
HPAF cells express components for different autocrine
growth pathways 
The binding of [125I]-EGF, -GRP or IGF-I to HPAF cells was
specific and could be competitively prevented with unlabelled
ligand (Figure 1A–C). Approximately 100-fold more unlabelled
insulin was required to inhibit the binding of [125I]-IGF-I than
[125I]-insulin to HPAF cells (Figure 1C). The chromatographs
for gel permeation analysis of the peptide fractions from 
HPAF-conditioned medium showed that TGFa, GRP and IGF-
I-like immunoreactivity were eluted in the same position as the
corresponding synthetic peptide (Figure 1D–F). GRP-like
immunoreactivity was detected in a major peak corresponding to
GRP and in a minor immunoreactive peak with the Ve of
neuromedin C (Figure 1E). 
Frequent change of medium prevents autocrine growth
stimulation 
The [3H] thymidine incorporation into HPAF cells after 72, 96
and 120 hours of continuous culture was significantly higher
than into cells receiving fresh serum-free medium every 12 hours
(Figure 2). Cell number also increased significantly after 96 and
120 hours but not after 72 hours (Figure 2). [3H-methyl] thymi-
dine incorporation into HPAF cells, receiving fresh serum-free
medium every 12 hours, during a 120-hour time course, did not
significantly change (72 h, 4580 ± 480 cpm; 96 h, 4660 ± 780
cpm; 120 h, 5330 ± 620 cpm). Frequent changes of medium
also had a significant inhibitory effect on the proliferation of
CAPAN-2, SW1990 and PANC-1 pancreatic cancer cells 
(P < 0.01, n = 6). 
EGF receptor function is required for autocrine growth
factor action in pancreatic cancer cells 
The increase in [3H] thymidine incorporation into HPAF DNA due to
soluble endogenous growth factors was completely inhibited by the
EGF receptor tyrosine kinase inhibitor, AG1478 or an EGF analogue,
[Abu20,31]hEGF(20–31)-NH2 (Figure 3A). Both AG1478 and
[Abu20,31]hEGF(20–31)-NH2 inhibited thymidine incorporation in a
concentration-dependent manner (Figure 4A and C, respectively).
In contrast, the GRP receptor antagonist, RC3950-II, or the IGF-I
receptor blocking antibody, aIR3, had no effect on the thymidine
incorporation into cells cultured continuously for 4 days (Figure 3A
and B). The [3H] thymidine incorporation into HPAF cells cultured in
the presence of 10 mM AG1478 was lower than that into cells
receiving fresh serum-free medium every 12 hours. AG1478 also
significantly reduced the number of HPAF cells grown continuously
for 96 hours (P < 0.05, n = 5; data not shown). When HPAF cells
were exposed to 1 nM EGF after 72 hours of continuous culture in
serum-free medium, [3H] thymidine incorporation increased signifi-
cantly (Figure 4B and D). This increase was completely prevented
by 10 mM AG1478 (Figure 4B) or [Abu20,31]EGF(20–31)-NH2
(Figure 4D). 
Affinity-purified anti-TGFa IgG had no significant effect on the
[3H] thymidine incorporation into HPAF cells cultured continu-
ously (Figure 5A) but did inhibit incorporation induced by exoge-
nous TGFa (Figure 5B). In contrast, when cells were cultured
continuously in the presence of heparin, [3H] thymidine incorpora-
tion was inhibited in a concentration-dependent manner (Figure
5C). Heparin had no effect on EGF-induced [3H] thymidine incor-
poration into HPAF cells but did inhibit the growth effect observed
with recombinant amphiregulin (data not shown). The amphireg-
ulin monoclonal antibody, 16.21.28, significantly inhibited the
incorporation of [3H] thymidine into these cells (Figure 5D). 
Autocrine activation of EGF receptors leads to
ERK1/ERK2 activation 
The cell permeable inhibitor of MEK1/2, PD098059, significantly
inhibited the proliferation of HPAF cells (Figure 6A). The prolifer-
ation of CAPAN-2 cells cultured continuously in serum-free
medium was completely inhibited by PD098059, as well as to
AG1478 (Figure 6B). To detect changes in ERK-MAPK activation
in CAPAN-2 cells, culture conditions were scaled up. Although
exogenous EGF had no significant effect on the activity of
ERK1/ERK2 in CAPAN-2 cells, PD098059 significantly inhib-
ited the activity of ERK1/ERK2 in CAPAN-2 cells cultured
continuously in serum-free medium. Using conditions identical
to those for Figure 6C, the proportion of CAPAN-2 cells in S
phase after 6 hours of continuous culture in serum-free medium
928 LO Murphy et al 
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Autocrine activation of EGF receptors increases
expression of AP-1 genes 
The steady-state level of c-fos and c-jun mRNA in CAPAN-2 cells
cultured continuously in serum-free medium increased transiently
and after 6 hours, the mRNA levels returned to those measured in
cells at the start (Figure 7A and B). When cells were cultured in
the presence of AG1478 or PD098059, the level of c-jun mRNA
Autocrine growth factors and pancreatic cancer 929
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was reduced to baseline levels (Figure 7C). The levels of c-fos
mRNA after one hour of culture was similarly reduced by
PD098059 or AG1478 (data not shown). FACs analysis showed
the distribution of cells in S phase increased with time of culture in
serum-free medium, peaking after 9 hours (data not shown). [3H]
thymidine incorporation similarly increased with time, reaching a
maximum at 12 hours and decreasing thereafter (Figure 7D). In
contrast, when cells were cultured in a larger volume of medium,
20 ml rather than 4 ml, the peak of [3H] thymidine incorporation
was sustained for a longer period (20–36 hours). 
DISCUSSION 
In this study, the role of different autocrine growth factor pathways
in the proliferation of human pancreatic cancer cells was exam-
ined. The expected observation that HPAF cells express binding
sites for EGF and GRP is in agreement with the results of previous
studies using other cell lines (Korc, 1991; Wang et al, 1996). Since
unlabelled insulin was approximately 100-fold more effective in
competitive inhibition of the binding of [125I]-insulin compared to
[125I]-IGF-1, it is likely that HPAF cells express high-affinity
binding sites for IGF-I. Soluble ligands for the EGF, GRP and
IGF-I receptors were also present in HPAF-conditioned medium.
These observations suggest that several autocrine growth pathways
actively promote the proliferation of HPAF cells in vitro. When
pancreatic cancer cells received frequent changes of medium, [3H-
methyl] thymidine incorporation and cell numbers were decreased,
indicating that ligands such as TGFa, GRP or IGF-I potentially
mediate autocrine stimulation of cells. Since [3H-methyl] thym-
idine incorporation did not change in cells that received frequent
medium changes, it seems likely that this approach is successful
for making pancreatic cancer cells quiescent in vitro. Thus, the cell
culture system employed here revealed a direct role for autocrine
growth factors in the proliferation of pancreatic cancer cells. 
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Surprisingly, inhibiting the function of the EGF-receptor with
an EGF receptor tyrosine kinase inhibitor, AG1478 (Osherov and
Levitzki, 1994) but not a GRP receptor antagonist (RC3950-II) or
an IGF-I receptor blocking antibody (aIR3) inhibited the prolifera-
tion of HPAF cells cultured continuously in serum free medium.
AG1478 had no effect on IGF-1-stimulated proliferation in HPAF
or PANC-1 cells; a further indication of the specificity of this
agent for the EGF receptor tyrosine kinase (unpublished observa-
tions). CAPAN-2 and SW1990 pancreatic cancer cells were also
sensitive to EGF receptor inhibition (unpublished observations).
This indicates that the GRP and IGF-I receptor-mediated autocrine
pathway is not functionally active under standard in-vitro condi-
tions. We and others have suggested a role for a bombesin-like
autocrine growth pathway in pancreatic cancer (Qin et al, 1994;
Wang et al, 1996). These studies showed that the components of a
bombesin-like autocrine growth pathway were expressed by pancre-
atic cancer cells and that a GRP receptor antagonist could inhibit the
modest growth effect of exogenous GRP receptor ligands. The
present study indicates that endogenous GRP and neuromedin C do
not contribute to autocrine growth in pancreatic cancer cell lines.
The effect of [Abu20,31]hEGF (20–31)-NH2 on [3H-methyl]
thymidine incorporation provides further evidence that soluble
endogenous EGF-like growth factors mediate autocrine growth
effects in HPAF cells. This synthetic EGF analogue, competes for
125I-EGF binding in a concentration-dependent manner (unpublished
observations). Like AG1478, [Abu20,31] hEGF (20–31)-NH2 reduced
[3H-methyl] thymidine incorporation below control levels,
suggesting that the autocrine pathway detected may still be partly
active in cells which received serum-free media every 12 hours (due
to residual factors remaining after the medium change). Recently,
potato carboxypeptidase inhibitor was shown to be an effective
inhibitor of binding of EGF to receptors on pancreatic cancer cells
but it had no effect on basal cell proliferation (Blanco-Aparicio et al,
1998). It is likely that the particular choice of cell density and
medium volume in this study is responsible for the lack of effect. 
Exogenous EGF was able to stimulate [3H-methyl] thymidine
incorporation into cells cultured continuously, suggesting that
endogenous growth factors are not maximally stimulating cells
during continuous culture. It is also possible that the signaling
pathways activated by recombinant EGF are different from those
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activated by the endogenous EGF-like autocrine factors, leading to
different effects on cell proliferation. 
The inability of the anti-TGFa IgG to affect proliferation of
HPAF or CAPAN-2 cells cultured continuously indicates that
TGFa is not a functional autocrine growth factor, despite being
readily detected in medium conditioned by pancreatic cancer cells.
A previous study showed that an anti-TGFa IgG could partially
inhibit PANC-1 cell proliferation (Wagner et al, 1996). It is likely
that differences between pancreatic cancer cell lines and experi-
mental procedures could explain this discrepancy. Nevertheless, in
the present study, the effect of the anti-TGFa IgG on exogenous
recombinant TGFa shows that the IgG can inhibit the bioactivity
of a concentration of TGFa which exceeds that produced by
pancreatic cancer cells under the experimental conditions used. It
is also possible that the concentration of endogenous TGFa
secreted into the culture medium may be too low to have a mito-
genic effect. Other investigators have found that immuno-neutral-
izing endogenous TGFa does not inhibit cancer cell proliferation
(Mulder and Brattain, 1989), but a TGFa antisense oligonu-
cleotide does (Howell et al, 1998). This group and others 
(Hollande et al, 1997) have suggested that ligand-receptor
complexes could be involved in signalling in the cytosol by an
intracrine mechanism.
The inhibitory effect of heparin on the proliferation of HPAF
cells cultured continuously in serum-free medium indicates that
the functional autocrine growth factors produced by these cells
contain heparin-binding domains. However, the proliferation of
cells in the presence of heparin (100 mg ml–1) remained higher than
that of cells cultured in fresh medium every 12 hours which
suggests that other EGF-like factors, in addition to those which
bind heparin, are involved in autocrine growth regulation. Heparin
has been used in the present study as a potential modulator of
heparin-binding growth factor activity. Any change in cell prolif-
eration in the presence of heparin can indicate the importance of
heparin-binding growth factors (Cook et al, 1991; Jayson and
Gallagher, 1997). The effect of heparin on EGF-stimulated prolif-
eration of pancreatic cancer cells is consistent with another study
which showed that heparin sulphate does not affect the TGFa-
stimulated clonal growth of human keratinocytes (Cook et al,
1991). Other investigators have provided evidence to suggest that
HB-EGF-like growth factor and amphiregulin may play important
roles in growth regulation of human pancreatic cancer (Ebert et
al, 1994; Schuger et al, 1996; Kobrin et al, 1994; Funatomi et
al, 1997). Since heparin had no effect on EGF-stimulated prolifer-
ation in the present study, it is likely that exogenous heparin inter-
acts with the basic amino acid residues in the amino-terminal
regions of endogenous amphiregulin and/or HB-EGF (Schuger et
al, 1996) thus preventing productive interactions between these
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16.21.28 (10 mg ml–1) (D) for 96 hours. During the final 24 hours of continuous culture, cells were incubated with or without 1 nM TGFa in the presence and
absence of anti-TGFa IgG (B). The data are expressed as a percentage of the [3H-methyl] thymidine incorporation into cells cultured in new medium every 12
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ligands and the EGF receptor. Experiments using monoclonal anti-
body 16.21.28 confirms that HPAF cells proliferate in serum-free
medium, at least in part, by autocrine stimulation from endogenous
amphiregulin. 
PD098059 significantly inhibited the proliferation of all cell
lines suggesting that autocrine activation of EGF receptors leads to
activation of the ras/MEK/ERK pathway. This was confirmed by
the observation that GST-Elk-1 was significantly phosphorylated
by ERK1/ERK2 from CAPAN-2 cells when cultured continuously.
Although cell proliferation of CAPAN-2 cells was increased
by exogenous EGF, ERK activity was not further increased. This
supports the idea that exogenous EGF may activate signalling
pathways which are distinct from those activated by endogenous
EGF-like factors. Cell cycle analysis shows that the number of
CAPAN-2 cells in S phase after 6 hours of continuous culture is
reduced in the presence of AG1478 or PD098059. These experi-
ments were performed to show that these inhibitors are also effec-
tive in a larger scale study in which larger medium volume and
more cells are used. 
The kinetics and magnitude of the increase in c-jun and c-fos
mRNA are consistent with the effect of growth factors, such as
EGF, on the expression of these genes (Greenberg and Ziff, 1984;
Quantin and Breathnach, 1988). The culture environment in which
mRNA levels have been monitored in the present investigation
permits the interpretation that endogenous growth factors signal
through the EGF receptor and ras/raf/MEK pathway leading to an
increase in c-fos or c-jun mRNA. In these experiments, [3H-
methyl] thymidine incorporation increased with culture time,
revealing that the increase in c-fos and c-jun mRNA precedes that
of DNA synthesis and cell proliferation. 
It is possible that the observed changes in AP-1 gene expression
in CAPAN-2 cells is due to stress arising from the addition of serum-
free medium to cells and is not a response to soluble endogenous
growth factors. It has been reported that fluid shear-stress can acti-
vate the MAPK pathway and induce c-jun transcriptional activity in
vascular endothelial cells (Li et al, 1996). In the present study, a role
for stress, potentially due to the physical addition of serum-free
medium, is unlikely since the rate and magnitude of [3H-methyl]
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thymidine incorporation into CAPAN-2 decreased when the volume
of serum-free medium was increased. This indicates that the
observed growth effects are dependent on the local concentration of
endogenous autocrine growth factors in the culture medium and not
to shear stress. The result also suggests that the accumulation of
endogenous growth factors is slower in 20 ml than in 4 ml of
medium. This is consistent with earlier results showing that the
proliferation of cells increased with culture time. By establishing a
larger ratio of cell number to medium volume, a submaximal prolif-
erative effect was achieved. This experiment also revealed that
pancreatic cancer cells can undergo a transient or a sustained prolif-
erative response to endogenous autocrine factors. Sustained mito-
genic activity is likely to correspond with the growth phenotype in
vivo. Future study of the signalling pathways required for sustained
growth may provide new information on the mechanisms respons-
ible for transducing autocrine signals in pancreatic cancer cells. 
ACKNOWLEDGEMENTS 
The authors are grateful for the kind gifts of amphiregulin neutral-
izing monoclonal antibody 16.21.28 from Dr Bruce Cohen, Bristol
Myers Squibb (Seattle, WA) and the IGF-I receptor monoclonal
antibody aIR3 from Dr Steve Jacobs (Burroughs Wellcome Co.,
Research Triangle Park, NC). These studies were funded by grants
from the Nebraska State Cancer and Smoking Related Disease
Program (LB595), the Swedish Cancer Foundation (3450-
B95-03xcc and 2870-B96-06xac) and the Carpenter Chair in
Biochemistry, Creighton University. 
REFERENCES 
Apple SK, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL and Grody WW
(1996) Polymerase chain reaction based K-ras mutation detection of
0
0
15
45
30
60
4 8 10 16 20 24
Hours
28 32 36 40 44 48
[
3
H
]
-
t
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
(
c
p
m
·
1
0
3
)
0
0 0.5 1
Hours
26
5
10
15
c
-
j
u
n
 
m
R
N
A
(
f
m
o
l
/
m
g
 
R
N
A
)
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7
700
200
18192021
0
012
Hours
6
25
50
75
100
c
-
f
o
s
 
m
R
N
A
(
f
m
o
l
/
m
g
 
R
N
A
)
300
200
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7
0
5
10
15
hours
AG1478
PD098059
0111
+
+
- - -
---
P < 0.01
P < 0.0001 P < 0.01
c
-
j
u
n
 
m
R
N
A
(
f
m
o
l
/
m
g
 
R
N
A
)
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7
700
600
AB
CD
Figure 7 Quantitative competitive RT-PCR analysis of c-fos and c-jun mRNA in CAPAN-2 cells. After 0, 0.5, 1, 2 or 6 hours of continuous culture in serum-free
medium (A, B) or 1 hour of culture in the presence and absence of 10 mM AG1478 or 20 mM PD098059 (C), total RNA was extracted from CAPAN-2 cells and
mRNA levels were determined as described in the Methods section. The data are expressed as the number of fmoles of c-fos or c-jun mRNA per mg of total
RNA. The amount of cRNA in each RT-PCR tube was 14.1 (lanes 2, 6, 10, 14 and 18), 1.41 (lanes 3, 7, 11, 15 and 19), 0.141 (lanes 4, 8, 12, 16 and 20) and
0.028 fmoles (lanes 5, 9, 13, 17 and 21). Molecular weight standards (base pairs) are shown in lane 1. Data shown represent the mean ± SEM from 2 (A, B) or
3 (C) separate experiments. [3H-methyl] thymidine incorporation into CAPAN-2 cells cultured continuously in 4 ml (solid circles) or 20 ml (open circles) of
medium was also determined (D) Autocrine growth factors and pancreatic cancer 935
British Journal of Cancer (2001) 84(7), 926–935 © 2001 Cancer Research Campaign
pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 105:
321–326 
Blanco-Aparicio C, Molina MA, Fernandez-Salas E, Frazier ML, Mas JM, Querol E,
Aviles FX and de Llorens R (1998) Potato carboxypeptidase inhibitor, a T-knot
protein, is an epidermal growth factor antagonist that inhibits tumor cell
growth. J Biol Chem 273: 12370–12377 
Cook PW, Mattox PA, Keeble WW, Pittelkow MR, Plowman GD, Shoyab M,
Adelman JP and Shipley GD (1991) A heparin sulfate-regulated human
keratinocyte autocrine factor is similar or identical to amphiregulin. Mol Cell
Biol 11: 2547–2557 
Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Buchler MW, Johnson GR
and Korc M (1994) Induction and expression of amphiregulin in human
pancreatic cancer. Cancer Res 54: 3959–3962 
Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR and Korc M
(1997) Amphiregulin antisense oligonucleotide inhibits the growth of T3M4
human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted
therapy. Int J Cancer 72: 512–517 
Greenberg ME and Ziff EB (1984) Stimulation of 3T3 cells induces transcription of
the c-fos proto-oncogene. Nature (Lond) 311: 433–437 
Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT,
Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE
(1996) DPC4, a candidate tumor suppressor gene at human chromosome
18q21.1. Science 271: 350–353 
Hollande F, Imdahl A, Mantamadiotis T, Ciccotosto GD, Shulkes A and Baldwin GS
(1997) Glycine-extended gastrin acts as an autocrine growth factor in a non-
transformed colon cell line. Gasterenterol 113: 1576–1588 
Howell GM, Humphrey LE, Ziober BL, Awwad R, Periyasamy B, Koterba A, Li W,
Willson JKV, Coleman K, Carboni J, Lynch M and Brattain MG (1998)
Regulation of transforming growth factor a expression in a growth factor-
independent cell line. Mol Cell Biol 18: 303–313 
Jayson GC and Gallagher JT (1997) Heparin oligosaccharides: inhibitors of the
biological activity of bFGF on Caco-2 cells. Br J Cancer 75: 9–16 
Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P and Korc M (1994)
Induction and expression of heparin-binding EGF-like growth factor in human
pancreatic cancer. Biochem Biophys Res Comm 202: 1705–1709 
Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Buchler MW, Johnson GR
and Korc M (1994) Induction and expression of amphiregulin in human
pancreatic cancer. Cancer Res 54: 3959–3962 
Korc M (1991) Growth factors and pancreatic cancer. Int J Pancreatol 9: 87–91 
Kull FC, Jacobs S, Su Y-F, Svoboda ME, van Wyk JJ and Cuatrecasas P (1983)
Monoclonal antibodies to receptors for insulin and somatomedin C. J Biol
Chem 258: 6561–6566 
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head
of bacteriophage T4. Nature (Lond) 227: 680–685 
Landis SH, Murray T, Bolden S and Wingo PA (1999) Cancer Statistics, 1999. CA
Cancer J Clin 49: 8–31 
Li Y-S, Shyy JY-J, Li S, Lee J, Su B, Karin M and Chien S (1996) The ras-JNK pathway
is involved in shear-induced gene expression. Mol Cell Biol 16: 5947–5954 
Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, Lynch JF,
Fusaro LR, Fusaro RM and Ghadirian P (1996) Familial pancreatic cancer: a
review. Semin Oncol 23: 251–275 
Mulder KM and Brattain MG (1989) Effects of growth stimulatory factors on
mitogenicity and c-myc expression in poorly-differentiated and well-
differentiated human colon carcinoma cells. Mol Endocrinol 3: 1215–1222. 
Munehiro Y, Ebert M and Funatomi H (1994) Amphiregulin is a potent mitogen in
human pancreatic cancer cells: correlation with patient survival. Int J Oncol 6:
625–631 
Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T and Shizume
K (1990) Insulin-like growth factors in human pancreatic cancer cell growth.
Cancer Res 50: 103–107 
Osherov N and Levitzki A (1994) Epidermal-growth-factor-dependent activation of
the Src-family kinases. Eur J Biochem 225: 1047–1053 
Ötvös FL, Murphy RF and Lovas S (1994) Coupling difficulty following
replacement of Tyr with HOTic during synthesis of an analog of an EGF 
B-loop fragment. J Pept Res 53: 302–307 
Qin Y, Ertl T, Cai R-Z, Halmos G and Schally AV (1994) Inhibitory effect of
bombesin receptor antagonist RC-3095 on the growth of human pancreatic
cancer cells in vivo and in vitro. Cancer Res 54: 1035–1041 
Qin Y, Ertl T, Cai R-Z, Horvath JE, Groot K and Schally AV (1995) Antagonists of
bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human
pancreatic adenocarcinoma and production of cyclic AMP. Int J Cancer 63:
257–262 
Quantin B and Breathnach R (1988) Epidermal growth factor stimulates transcription of
the c-jun proto-oncogene in rat fibroblasts. Nature (Lond) 334: 538–539 
Schuger L, Johnson GR, Gilbride K, Plowman GD and Mandel R (1996)
Amphireguln in lung branching morphogenesis: Interaction with heparin
sulfate proteoglycan modulates cell proliferation. Development 122:
1759–1767 
Skullman S, Adrian TE, Permert J, Larsson J (1994) Humoral growth factors in
plasma and liver tissue during liver regeneration and malnutrition. Eur J
Gastroenterol Hepatol 6: 797–802 
Wagner M, Cao T, Lopez ME, Hope C, van Nostrand K, Kobrin MS, Fan HU,
Buckler MW and Korc M (1996) Expression of a truncated EGF receptor is
associated with inhibition of pancreatic cancer cell growth and enhanced
sensitivity to cisplatinum. Int J Cancer 68: 782–787 
Wang QJ, Knezetic JA, Schally AV, Pour PM and Adrian TE (1996) Bombesin may
stimulate proliferation of human pancreatic cancer cells through an autocrine
pathway. Int J Cancer 68: 1–7 